公开(公告)号：US20060105029A1

公开(公告)日：2006-05-18

申请号：US11271114

申请日：2005-11-10

申请人： Jie Zhang ,  Kevin Warner

发明人： Jie Zhang ,  Kevin Warner

IPC分类号： A61F13/02 ,  A61L15/16

CPC分类号： A61K9/703 ,  A61K9/7084 ,  A61L15/16 ,  A61L15/44 ,  A61L15/60 ,  A61L2300/40 ,  A61L2300/602

摘要： The present invention is drawn toward systems, devices, and methods of dermal drug delivery. The system can comprise a gel-triggering agent and a drug-containing composition including a drug and a gelling agent, wherein the drug-containing composition forms a soft, coherent solid when contacted with the gel-triggering agent. A cavity patch is also included having an open cavity configured to be closed at least in part by a skin surface. The open cavity can be further configured to facilitate contact between the skin surface and the gel. The gel-triggering agent and the drug-containing composition can be positioned in the system such that they are kept isolated from one another until immediately before or during use.

摘要翻译： 本发明涉及皮肤药物递送的系统，装置和方法。 该系统可以包含凝胶引发剂和包含药物和胶凝剂的药物组合物，其中当与凝胶引​​发剂接触时，含药组合物形成柔软的粘连固体。 还包括空腔贴片，其具有被构造为至少部分地被皮肤表面封闭的开口腔。 开放空腔可进一步构造成促进皮肤表面和凝胶之间的接触。 凝胶引发剂和含药物的组合物可以定位在系统中，使得它们彼此隔离直到使用前或使用前。

公开(公告)号：US20060105028A1

公开(公告)日：2006-05-18

申请号：US11271020

申请日：2005-11-10

申请人： Jie Zhang ,  Kevin Warner

发明人： Jie Zhang ,  Kevin Warner

IPC分类号： A61F13/02 ,  A61L15/16

CPC分类号： A61K9/703 ,  A61F13/063 ,  A61K9/7084 ,  A61L15/16 ,  A61L15/44 ,  A61L15/60 ,  A61L2300/40 ,  A61L2300/602

摘要： The present invention is drawn to systems and methods for treating warts. The system can comprise a wart treatment formulation comprising a substance for treating warts and a cavity patch comprising an open cavity being configured to become a closed cavity upon application and adherence to a skin surface. The closed cavity can be configured to contain the wart treatment formulation.

摘要翻译： 本发明涉及用于治疗疣的系统和方法。 该系统可以包括疣治疗制剂，其包括用于治疗疣的物质和包括开放腔的空腔补片，该开放腔被构造成在施用时粘附到皮肤表面上成为闭合腔。 闭合的腔体可以构造成容纳疣治疗制剂。

公开(公告)号：US20050276842A1

公开(公告)日：2005-12-15

申请号：US11146917

申请日：2005-06-06

申请人： Jie Zhang ,  Kevin Warner ,  Michael Ashburn ,  Larry Rigby ,  Suyi Niu

发明人： Jie Zhang ,  Kevin Warner ,  Michael Ashburn ,  Larry Rigby ,  Suyi Niu

IPC分类号： A61K9/70

CPC分类号： A61K9/7015 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/445 ,  A61K31/573 ,  A61K47/10 ,  A61K47/32

摘要： The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated.

摘要翻译： 本发明涉及用于药物真皮递送的粘合剂剥离形成制剂。 制剂可以包括药物，溶剂载体和剥离形成剂。 溶剂载体可以包括具有一种或多种挥发性溶剂的挥发性溶剂体系和具有一种或多种非挥发性溶剂的非挥发性溶剂体系，其中所述非挥发性溶剂体系对于在窗口内的药物具有溶解性 对药物具有可操作的溶解性，使得药物可以在持续的时间段内以治疗有效率递送。 在挥发性溶剂体系蒸发之前，配方可以具有适用于皮肤表面的粘度。 当施用于皮肤时，在挥发性溶剂体系的至少一部分蒸发之后，制剂可以形成固化的可剥离层。

公开(公告)号：US06955819B2

公开(公告)日：2005-10-18

申请号：US09796250

申请日：2001-02-28

申请人： Jie Zhang ,  Wade Hull ,  Larry Rigby ,  Theodore Stanley

发明人： Jie Zhang ,  Wade Hull ,  Larry Rigby ,  Theodore Stanley

IPC分类号： A61F7/03 ,  A61F13/00 ,  A61K9/00 ,  A61K9/70 ,  A61M31/00 ,  A61N1/30

CPC分类号： A61K9/0024 ,  A61F7/032 ,  A61F2013/00646 ,  A61K9/0004 ,  A61K9/0009 ,  A61K9/703 ,  A61M31/002 ,  A61M2037/0007 ,  A61N1/30

摘要： The present invention is directed toward an apparatus to rapidly deliver a drug to a patient The invention comprises a drug beneath a patient's skin in a drug depot site. A heating component is placed near the drug depot site and generates heat in and near the drug depot site. A control component connected to the heating component is used to control the magnitude and duration of heat generated by the heating component.

摘要翻译： 本发明涉及一种将药物快速输送给患者的装置。本发明包括在药物库位点的患者皮肤下面的药物。 加热部件放置在药物库位附近，并在药物库位置内和附近产生热量。 连接到加热部件的控制部件用于控制由加热部件产生的热量的大小和持续时间。

公开(公告)号：US20050221342A1

公开(公告)日：2005-10-06

申请号：US10972024

申请日：2004-10-22

申请人： Y. Tang ,  Vinod Asundi ,  Ping Zhou ,  Aidong Xue ,  Feiyan Ren ,  Jie Zhang ,  Jian-Rui Wang ,  Yonghong Yang ,  Qing Zhao ,  Ryle Goodrich ,  Chenghua Liu ,  Radoje Drmanac ,  Yunqing Ma ,  Zhiwei Wang ,  Tom Wehrman

发明人： Y. Tang ,  Vinod Asundi ,  Ping Zhou ,  Aidong Xue ,  Feiyan Ren ,  Jie Zhang ,  Jian-Rui Wang ,  Yonghong Yang ,  Qing Zhao ,  Ryle Goodrich ,  Chenghua Liu ,  Radoje Drmanac ,  Yunqing Ma ,  Zhiwei Wang ,  Tom Wehrman

IPC分类号： C07H21/04 ,  C07K14/47 ,  C12N15/09 ,  C12Q1/68

CPC分类号： C07K14/47 ,  C12Q1/6837

摘要： The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

公开(公告)号：US20050196349A1

公开(公告)日：2005-09-08

申请号：US10849067

申请日：2004-05-19

申请人： Dianqing Wu ,  Yazhou Zhang ,  Peng Liu ,  Xiaofeng Li ,  Jie Zhang ,  Jufang Shan ,  Dean Engelhardt

发明人： Dianqing Wu ,  Yazhou Zhang ,  Peng Liu ,  Xiaofeng Li ,  Jie Zhang ,  Jufang Shan ,  Dean Engelhardt

IPC分类号： A61K9/68 ,  G01N33/48 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68 ,  G06F19/00 ,  A61K7/28

CPC分类号： G01N33/6893 ,  A61K38/00 ,  G01N33/6887 ,  G01N2500/00 ,  G01N2800/10 ,  G01N2800/108

摘要： The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.

摘要翻译： 研究了Wnt共同受体LRP5的高骨量（HBM）突变（G171V）调节规范Wnt信号传导的机制。 以前显示突变可以降低Dkk蛋白-1介导的拮抗作用，这表明G171位于第一个YWTD重复结构域可能是Dkk蛋白介导的拮抗作用的原因。 然而，我们发现第三个YWTD重复，但不是第一个重复结构域，是DKK1介导的拮抗作用所必需的。 相反，我们发现G171V突变破坏了LRP5与Mesd的相互作用，Mesd是共受体转运到细胞表面所需的LRP5 / 6的伴侣蛋白，导致细胞表面上较少的LRP5分子。 尽管细胞表面LRP5分子水平的降低导致旁分泌范例中Wnt信号传导的降低，但突变似乎不影响共表达Wnt在自分泌范式中的活性。 连同观察到成骨细胞产生自分泌的正常Wnt，Wnt7b，并且该骨细胞产生旁分泌的Dkk1，我们认为G171V突变可能通过减少旁分泌Dkk1靶向拮抗的数目而引起成骨细胞中Wnt活性的增加，而不影响 自分泌Wnt的活性。

公开(公告)号：US20050182012A1

公开(公告)日：2005-08-18

申请号：US11004512

申请日：2004-12-02

申请人： Leslie McEvoy ,  Christi Parham ,  Jie Zhang ,  Rolf Ehrhardt

发明人： Leslie McEvoy ,  Christi Parham ,  Jie Zhang ,  Rolf Ehrhardt

IPC分类号： A61K48/00 ,  C07H21/04 ,  C12N15/113 ,  C12N15/115

CPC分类号： C12N15/115 ,  C12N15/113 ,  C12N2310/13 ,  C12N2310/315 ,  C12N2310/345 ,  C12N2310/53

摘要： The present invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that contain a core sequence capable of specific binding to an NF-κB transcription factor. In a particular aspect, the invention concerns NF-κB decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention concerns NF-κB decoy molecules with improved binding affinity to p65.

摘要翻译： 本发明涉及含有能够与NF-κB转录因子特异性结合的核心序列的双链NF-κB诱饵寡脱氧核苷酸（NF-kappaB dsODN）分子。 在一个特定方面，本发明涉及在p50 / p50同源二聚体上优先结合p50 / p65和/或cRel / p50异二聚体的NF-kappaB诱饵分子。 另一方面，本发明涉及对p65具有改善的结合亲和力的NF-κB诱饵分子。

公开(公告)号：US06723733B2

公开(公告)日：2004-04-20

申请号：US09854455

申请日：2001-05-15

申请人： Jia-He Li ,  Vincent J. Kalish ,  Jie Zhang ,  Larisa E. Serdyuk ,  Dana Victor Ferraris ,  Ge Xiao ,  Paul W. Kletzly

发明人： Jia-He Li ,  Vincent J. Kalish ,  Jie Zhang ,  Larisa E. Serdyuk ,  Dana Victor Ferraris ,  Ge Xiao ,  Paul W. Kletzly

IPC分类号： A61K31473

CPC分类号： C07D401/06 ,  C07D221/12

摘要： This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.

摘要翻译： 本发明涉及化合物，药物组合物和使用所公开的化合物抑制PARP的方法。

公开(公告)号：US06635642B1

公开(公告)日：2003-10-21

申请号：US09145176

申请日：1998-09-01

申请人： Paul F. Jackson ,  Jia-He Li ,  Keith M. Maclin ,  Jie Zhang

发明人： Paul F. Jackson ,  Jia-He Li ,  Keith M. Maclin ,  Jie Zhang

IPC分类号： A61K3150

CPC分类号： A61K31/4725 ,  C07C233/65 ,  C07D209/56 ,  C07D217/24 ,  C07D217/26 ,  C07D221/12 ,  C07D221/14 ,  C07D221/18 ,  C07D237/26 ,  C07D237/32 ,  C07D243/14 ,  C07D267/14 ,  C07D491/06 ,  C07D495/04 ,  C07D495/06

摘要： The present invention relates to PARP inhibitors, pharmaceutical compositions comprising the same, and methods of using the same to treat tissue damage resulting from cell damage or death due to necrosis or apoptosis, effect neuronal activities not mediated by NMDA toxicity; to treat neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn's disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and/or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), organ damage due to transplantation, and skin aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells.

摘要翻译： 本发明涉及PARP抑制剂，包含其的药物组合物及其用途，用于治疗由于坏死或凋亡引起的细胞损伤或死亡引起的组织损伤，影响不被NMDA毒性介导的神经元活性; 治疗由缺血和再灌注损伤，神经系统疾病和神经退行性疾病引起的神经组织损伤; 预防或治疗血管中风; 治疗或预防心血管疾病; 治疗年龄相关性黄斑变性，艾滋病和其他免疫衰老疾病，关节炎，动脉粥样硬化，恶病质，癌症，涉及复制衰老的骨骼肌退行性疾病，糖尿病，头部创伤，免疫衰老，炎性肠等其他病症和/或病症 疾病（如结肠炎和克罗恩病），肌营养不良症，骨关节炎，骨质疏松症，慢性和/或急性疼痛（如神经性疼痛），肾衰竭，视网膜缺血，败血性休克（如内毒素性休克），移植器官损伤 ，皮肤老化; 延长细胞的寿命和增殖能力; 改变衰老细胞的基因表达; 或放射性敏感的缺氧性肿瘤细胞。

公开(公告)号：US06453648B1

公开(公告)日：2002-09-24

申请号：US09347963

申请日：1999-07-06

申请人： Jie Zhang ,  Hao Zhang ,  Larry Rigby ,  Wade A. Hull

发明人： Jie Zhang ,  Hao Zhang ,  Larry Rigby ,  Wade A. Hull

IPC分类号： A61F700

CPC分类号： A61F7/034 ,  A61F2007/0226 ,  A61F2007/0249

摘要： The present invention relates to a method for manufacturing a heating device which is capable of generating heat when exposed to oxygen. The heat generating element comprises activated carbon and iron is used to generate an exothermic oxidation reaction within the heating device. Introducing an oxidation inhibitor during the manufacturing process allows the manufacturing of the device to take place in ambient atmospheric conditions. The present invention also includes a loading facilitator which allows the heat generating medium to be more easily and efficiently loaded into the heat generating device. When appropriate, the oxidation inhibitor and loading facilitator can be removed.

摘要翻译： 本发明涉及一种能够在暴露于氧气时产生热量的加热装置的制造方法。 发热元件包括活性炭和铁，用于在加热装置内产生放热氧化反应。 在制造过程中引入氧化抑制剂可使装置的制造在环境大气条件下进行。 本发明还包括能够使发热介质更容易且有效地装载到发热装置中的负载辅助装置。 适当时，可以除去氧化抑制剂和负载促进剂。